Mir A. Imran

Board Director

Director

Insider activity · 24 months2 buys0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 1 buy · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 1 buy · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (2 ops.)

€1.1M

▼ Sales (1 ops.)

€733k

Latest filing published 23 Jul 2026 for Rani Therapeutics Holdings, Inc., €22k. Read the official filing

Filing timeline

BuySale

Mir A. Imran

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-27.0%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Mir A. Imran: trading record in brief

All filings by Mir A. Imran on record concern Rani Therapeutics Holdings, Inc., in the capacity of board member. We count 6 filings; the first trade dates from 3 February 2022 and the latest from 21 July 2026.

The open-market side counts 2 purchases for €1.1M alongside 1 sale for €733k. On balance, insiders were net buyers of €373k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2026 to date brings 1 purchase and no sales.

Most recently, on 23 July 2026, the filings show an open-market purchase worth €22k in Rani Therapeutics Holdings, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.